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Background: Cancer survivors are a heterogeneous group with complex health problems. Data concerning its total
number and growing dynamics for Switzerland are scarce and outdated.
Methods: Population and mortality data were retrieved from the Swiss Federal Statistical Office (FSO). Incidence
and relative survival for invasive cancers were computed using data from the cancer registries Geneva (1970–2009),
St. Gallen - Appenzell (1980–2010), Grisons & Glarus (1989–2010), and Valais (1989–2010). We estimated prevalence
for 1990–2010 using the Prevalence, Incidence Approach MODel (PIAMOD) method. We calculated trends in
prevalence estimates by Joinpoint analysis. Projections were extrapolated using the above models and based on
time trends of the period 2007–2010.
Results: The estimated number of cancer survivors increased from 139′717 in 1990 (2.08% of the population) to
289′797 persons in 2010 (3.70%). The growth rate shows an exponential shape and was 3.3% per year in the period
2008 to 2010. Almost half of the survivors have a history of breast, prostate or colorectal cancer. Among cancer
survivors, 55% are women but the increases have been more marked in men (p < 0.01, 3.9% annual increase in men
vs. 2.7% in women since 2008). By the end of 2020 372′000 cancer survivors are expected to live in Switzerland.
Conclusions: There is a rapidly growing population of cancer survivors in Switzerland whose needs and concerns
are largely unknown.
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SwitzerlandBackground
As a consequence of improved life expectancy, of the
growth and the aging of the population, as well as cancer
awareness and early detection strategies the number of
new cancer cases has raised continuously in the last
30 years in Switzerland and worldwide [1]. At the same
time, due to earlier diagnosis and improved treatments,
cancer mortality has declined and survival rates have
improved [2,3]. The conjunction of these factors has led
to a large and rapidly growing number of cancer
survivors.* Correspondence: christian.herrmann@kssg.ch
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reproduction in any medium, provided the orThere are several definitions of cancer survivor. Here,
we use the term of cancer survivor to describe any
person alive with a previous diagnosis of cancer, following
the American Society of Clinical Oncology (ASCO) [4]
and others [5-7] who define survivorship as the “process
of living with, through and beyond cancer”, equalling the
definition of complete prevalence.
It is not until recently that the special needs of this
growing population of cancer survivors have been
brought into the focus of researchers and stakeholders.
In 2006 the Institute of Medicine (IOM) focused on the
transition from primary treatment to follow up care and
the necessity to provide patients with a comprehensive
care summary and follow-up plan for guidance on
follow-up care, prevention and health maintenance [8].
In 2010 a National Cancer Survivorship Initiative in
the UK recognized that not enough attention has beenral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and treatment and that action is needed in order to
support cancer survivors to live as healthy and active
a life as possible [9,10]. The ongoing needs of cancer
survivors in Switzerland have received insufficient
attention up to now.
Three distinct phases of cancer survival has been
proposed: the first includes the time from diagnosis to
the end of the initial treatment which may extend
from some months to several years, the second includes
the transition from treatment to extended survival and the
third represents the long-term survival [11].
Cancer survivors will have greater health needs than
the general population because the disease and/or treat-
ment may lead to long-term or permanent impairment.
Moreover, people with a history of cancer have an
elevated risk for new primary cancers than the general
population [12].
An increase in cancer survivors is expected to result in
a need for additional specialized health personnel [8],
and a substantial increase in training in survivorship
care to support the delivery of multidimensional primary
care for long-term survivors [13]. In a review from 2011,
Richardson et al. [7] identified growing concern that
the services required to meet the physical, social and
emotional needs of survivors have not been adequately
developed so far.
In order to adequately develop strategies and services
required to meet the needs of this growing population
updated epidemiological data is essential. In Switzerland,
data on the number, growing dynamics and character-
istics of cancer survivors are not available or outdated.
Last published data for Switzerland correspond to
prevalence estimates for 1992 and only for a limited
number of malignancies [14].
The aim of the present work is to provide estimates of
the number and characteristics of cancer survivors by
the end of 2010 and project trends until 2020 in order
to better understand the challenges that this booming
population poses to oncological and general health
services in the near future.
Methods
Data sources
To estimate the Swiss complete prevalence for the period
1990–2010, we used data provided by the registries
Geneva (1970–2009), St. Gallen - Appenzell (1980–2010),
Grisons-Glarus (1989–2010) and Valais (1989–2010).
These registries, that cover approximately 26% of the
Swiss population, are the only Swiss registries to satisfy
following conditions i) have published incidence data in
Cancer in 5 Continents Volume IX, ii) have incidence data
at least from 1990 onwards and iii) are able to provide
survival data. These data is routinely collected by theregistries as part of national and cantonal programs.
Following federal regulations, after anonymization ex-
cluding any identifiable information such as names
and exact dates these data can be used in epidemio-
logical studies without additional ethics committee
approval.
Persons presenting with invasive cancers (International
Classification of Disease, 10th edition, codes C0-C96,
D45-D47) except non melanoma skin cancers [C44])
were included in the study. Individuals with multiple
primaries were counted only once and considered to
be prevalent since the first diagnosis of invasive cancer
retrieved from the cantonal cancer registries. Aggregated
population and mortality data for the corresponding
cantons and for Switzerland by year, gender and age
were retrieved from the Swiss Federal Statistical Office
(FSO) [15].
Incident DCO (“death certificate only”) cases were
excluded, as the true incidence date is unknown. The
DCO rate was similar for all regions and varied in
1990–2010 in the different regions from 0.1-2.3% with
an overall average of 0.6%. Cancer patients lost to
follow-up were included and account for 3.8% (95%
Confidence Interval, CI: 3.6%-4.1%) of studied popula-
tion. This proportion declined during the study period
and was 0.2% in 2010.
Statistical methods
Complete cancer prevalence in Switzerland was estimated
in a 3-step process by gender and cancer site, with all
cancer sites being modelled as a single site. First, we
estimated yearly incidence counts for Switzerland by
single years of age using the pooled yearly incidence
rates by age of the aforementioned registries and the
population data of the FSO. Then, we estimated survival
in Switzerland as the relative survival in the pooled
cantons, where patients lost to follow-up were censored at
time of last contact. And finally, with these data plus
population and all-cause mortality data for Switzerland,
we modelled cancer prevalence using the Prevalence,
Incidence Approach MODel (PIAMOD) method [16].
The same software was used to project prevalence until
2020 basing the incidence estimation on the Age-Period-
Cohort model with a linear period drift based on the
period 2007 to 2010 and pertaining age and cohort effect.
The survival, number of newborns and mortality for all
competing causes are assumed to remain constant at the
level of 2010. The absolute number of prevalent cases
in 2020 was estimated by multiplying the projected
prevalence rates for 2020 by the population count
forecast of the FSO using their reference scenario
(scenario no. A-00-2010) [17].
The tabulated relative survival in 6 month intervals for
maximally 20 years of follow-up was calculated on the
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survival in Switzerland using the Ederer II method [18]
with the so called mixed-approach [19] by consecutive
3-year periods from 1981 to 2010 and 5 distinct age-
groups (0–14, 15–49, 50–69, 70–79, 80+). In the age
group of 80+ years olds survival was restricted to a follow
up duration of 15 years due to high variance in the sur-
vival estimates resulting from small number of cases.
The fit of the Age-Period-Cohort-model based inci-
dence and hence prevalence was first evaluated on
observed pooled incidence rates, and in a second step
the final model parameters were selected by maximizing
representativeness of the local data. Representativeness
was measured by the sum of squared differences of the
modelled expected mortality rates from observed na-
tional mortality rates. The observed national mortality
rates were obtained from FSO data following the inci-
dence selection criteria and using the applicable correc-
tion factors before the year 1995 because of the change
of the directive of mortality codification occurred in our
country [20]. For the final models the expected mortality
differed per year averagely 4% for women and 5% for
























Figure 1 Estimated number of cancer survivors in Switzerland by tim
non-melanoma skin cancers. Percentages denote increases in the period 19Temporal trends, their statistical significance and time
points with significant changes in trend were assessed
with Joinpoint models [21], using the JoinPoint Regression
program of the National Cancer Institute. Joinpoint
models were restricted to maximally 4 joinpoints and
with a Poisson model of variation. A Monte Carlo
Permutation method was used to test for a statistically
significant change in trends. In addition, the goodness
of fit of models with identity link (piecewise linear
models) or log-link (for calculating annual percentage
increases) was compared.
Aging trends in the population for 3 age groups (0–19,
20–64, 65–99) were analysed with Joinpoint models of
the same kind.
Results
Figure 1 shows the exponential increase in the estimated
number of those living with a history of cancer in
Switzerland between the years 1990 and 2010 by time
since diagnosis. Cancer survivors diagnosed less than
5 years ago constituted the largest group while the
biggest rise is observed among very long term (20 years
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cancer, gender, time since diagnosis and age group.
The highest increase of cancer survivors prevalence
was observed for prostate cancer with an almost 4
fold increase (+279% in 2010 vs. 1990), followed by
skin melanoma (+184%) and breast cancer (+115%),
all cancers with a high increase in incidence in the
period studied. The estimate number of all cancer survi-
vors was approximately 290′000 for the year 2010. For
prevalence rates, the same pattern was seen.
In the same lapse of time the population grew by 12%
(95% CI: 10%-15%) but the growth was unevenly among
age groups: while the age group 65 years old and older
grew by 36% (95% CI: 33%-38%) the number of those





Men 56′201 132′330 +136% [132
Women 83′516 157′467 +89% [ 8
Total 139′717 289′797 +108% [105
Time since diagnosis
< 1 year 18′113 28′029 +55% [ 5
1-4 years 43′759 80′340 +84% [ 7
5-9 years 30′235 69′368 +129% [118
10-19 years 29′844 69′481 +133% [123
20+ years 17′765 42′578 +140% [135
Total 139′717 289′797 +108% [105
Cancer type**
Breast 30′892 66′513 +115% [111
Prostate 12′012 45′421 +279% [267
Colorectal 16′186 28′567 +77% [ 7
Lung 4′689 7′833 +67% [ 5
Lymph./Leukaemia 13′470 26′086 +94% [ 9
Melanoma 8′367 23′743 +184% [177
Other 54′102 91′634 +70% [ 6
Total 139′717 289′797 +108% [105
Age group
0-14 740 1′061 +44% [ 3
15-49 21′192 36′285 +72% [ 5
50-69 53′236 112′657 +112% [110
70-79 37′565 77′033 +106% [ 95
80+ 26′984 62′761 +132% [112
Total 139′717 289′797 +108% [105
*CI Confidence Interval.
**Excluding non-invasive and non-melanoma skin cancers.Cancer incidence increased both in absolute numbers
from estimated 24′335 in 1990 to 32′875 in 2010 (p <
0.01) and in relative numbers from a rate of 362.5 /100′
000 in 1990 to 432.5/100′000 in 2010 (p < 0.01),while
mortality decreased from 226.9/100′000 in 1990 to
209.9/ 100′000 in 2010 (p < 0.01). At the same time
10-year observed survival increased by 24% (95% CI:
21%-28%) from 0.27 to 0.34.
The increase was assessed to be exponential in compar-
ing models assuming either piecewise linear or piecewise
exponential increase, with the latter having better fit. The
exponential increase, measured as annual percent change
(APC), was at all periods significantly different from zero
and higher in men than in women. In both genders the
APC values increased from 1990 until a period around thes and crude rates per 100′000 in Switzerland between
Prevalence
Rates per 100'000
[95%CI*] 1990 2010 Increase [95%CI*]
%-141%] 1′714.5 3′436.2 +101% [ 94%-108%]
5%- 92%] 2′431.8 3′962.6 +63% [ 60%- 66%]
%-111%] 2′081.5 3′703.5 +78% [ 74%- 83%]
1%- 60%] 269.8 417.6 +55% [ 51%- 60%]
6%- 93%] 651.9 1′196.9 +84% [ 76%- 93%]
%-141%] 450.4 1′033.5 +129% [118%-140%]
%-143%] 444.6 1′035.1 +133% [123%-143%]
%-145%] 264.7 634.3 +140% [134%-145%]
%-111%] 2′081.5 3′703.5 +78% [ 74%- 83%]
%-119%] 460.2 850.0 +85% [ 78%- 92%]
%-291%] 179.0 580.5 +225% [212%-239%]
4%- 79%] 241.1 365.1 +52% [ 49%- 55%]
5%- 79%] 69.9 100.1 +44% [ 36%- 53%]
2%- 96%] 200.7 333.4 +67% [ 57%- 78%]
%-191%] 124.6 303.4 +143% [140%-147%]
6%- 73%] 806.0 1′171.1 +46% [ 40%- 51%]
%-111%] 2′081.5 3′703.5 +78% [ 74%- 83%]
2%- 57%] 64.5 89.7 +40% [ 31%- 49%]
9%- 86%] 605.3 951.1 +57% [ 56%- 59%]
%-114%] 3′848.7 5′949.8 +54% [ 51%- 58%]
%-118%] 8′665.2 13′823.2 +60% [ 54%- 67%]
%-154%] 10′925.9 16′691.0 +53% [ 47%- 60%]
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Figure 2 Trend of prevalence of cancer survivors by type of cancer in Switzerland. Expressed as the percent of 1990 value by type of
cancer with highest incidence. Excluding non-invasive and non-melanoma skin cancers.
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the most recent (2008–2010) APC in the number of
cancer survivors was 3.3% (95% CI: 3.1%-3.5%).
The results of our projection model showed a further
continuation of this exponential increase for the next
10 years with an APC value close to the most recent
one. We have estimated that until 2020 the total number
of cancer survivors will increase by 28% to a total of
372′000 (i.e. 4.4% of the Swiss population). The
projected number of cancer survivors and their increase
since 2010 using the projection model by major cancer
sites and gender can be found in Additional file 1. The
biggest increases were predicted for melanoma and pros-
tate cancer, while female breast cancer survivors were
predicted to still be the biggest group.
Discussion
In Switzerland, the overall number of cancer survivors
has increased exponentially in the last 20 years and is
expected to rise by about 30% in the next 10 years. We
estimated that in 2010, 3.7% of the Swiss population
were living with a history of cancer. This trend is the
result of several factors i) the continuing advances in the
treatment of oncologic diseases, ii) the spread of early
detection of common types of cancer such as prostate,
breast cancer and melanoma and iii) demographic
changes: a growing segment of the aged population and
an increased life expectancy due to various reasons. In
particular, advances in treatment of cardiovascular
diseases lead to a significant reduction of premature
deaths [22].
Similar results both concerning trend and proportion
of the population with a history of cancer have beenreported in other European countries. In the Nordic
countries (Sweden, Finland, Denmark, Norway, Iceland)
3.4 to 4.1% of the population is estimated to be a cancer
survivor by the end of 2010 [23]. In the UK new estima-
tions suggest that 2 million people representing 3.1% of
the population live with a diagnosis of cancer in 2010
[24]. In Italy the projections for 2010 estimate that 4% of
women and 3% of men are cancer survivors [25].
Similar pattern has also been reported in the USA
[26] with estimated 13.7 millions of Americans alive
with a history of cancer on January 1, 2012.
In these publications a wide range of methods to esti-
mate cancer prevalence was used based on the availabil-
ity of data in time and space and the underlying
question.
The method we used was also applied in De Angelis
et al. [25] and is specifically designed to estimate cancer
prevalence in settings with incomplete registration, in
contrast to e.g. discrete time models [24] where a long
time series of cancer registry data is necessary. Add-
itionally, our approach allowed the investigation of
time trends and -in using Joinpoint regression- the
assessment of significant changes therein over time.
The exponential increase in the past 20 years is mainly
attributable to cancer incidence growth driven by screen-
ing uptake especially of prostate cancer and breast cancer
and to a lesser extent to the aging of the population.
PSA screening has lead in Switzerland and worldwide
[27] to 3-4- fold increases of incidence rates of prostate
cancer. Moreover, median age at diagnosis decreased,
further contributing to increases of survival and preva-
lence of prostate cancer survivors. The incidence rate
of breast cancer has also doubled although the reasons
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time considerable advances in treatments and supportive
care have been realised in breast cancer and other types of
cancers. In particular, the number of survivors with haem-
atological malignancies and lung cancer that has increased
by 94% and 67% respectively testifies of these advances.
It is not possible to predict with accuracy the total
number of survivors in the future. In order to reflect the
present situation we used for the projections the most
recent trends (e.g. those in period 2007–2010). Future
numbers will depend on the evolution of incidence,
survival and demographic changes, and therefore might
differ from current predicitons. E.g. incidence of breast
cancer will probably increase as a consequence of the very
recent introduction of mammography screening programs
in many of the German-speaking cantons.
Most cancer survivors living with a cancer diagnosis
since more than one and less than 5 years are in the
phase following initial treatment, some of them disease
free, others are under long term maintenance therapy
managing sequelae of their treatment. Most of the
cancer survivors in this phase will require additional
treatment or special surveillance for relapse. Symptoms
and problems may differ according to the type of cancer
and the type of treatment applied. Breast cancer survi-
vors may experience lymphedema of the arm, a common
side effect of breast cancer surgery and radiation therapy
that can develop soon after treatment or years later. Risk
of lymphedema is reduced when sentinel node-biopsy
rather than axillary dissection is performed to determine
if the tumour has spread. In Switzerland less than 50%
of women qualifying for sentinel node biopsy were oper-
ated with this technique in the years 2003 to 2005 [30].
Prostate cancer survivors treated with surgery or radi-
ation therapy for early disease may experience symptoms
and side effects of treatment including incontinence,
erectile dysfunction and bowel complications [31]. Long
term survivors of colorectal cancer may experience
bowel problems and distress regarding cancer, specially
fear of recurrence [32].
We have observed the biggest increases in number of
survivors among long-term survivors. Because of in-
creased life expectancy and improvement in therapies it
is anticipated that this group will grow substantially in
the coming decade. Late toxicities of therapies such as
cardiotoxicity after cytotoxic drugs, cognitive deficits,
osteoporosis etc., will develop in long-term survivors.
Moreover, this group is at enhanced risk to other pri-
mary cancers and may suffer of poorer health. Several
studies [33,34] have found that compared with individ-
uals without a history of cancer or other chronic disease
a substantial number of individuals who have a history
of cancer were significantly more likely to report poor
health and well-being, have a psychological disability,have limitations of activities of daily living and among
those under the age of 65, being unable to work because
of a health condition. These findings suggest the neces-
sity of developing specific support for cancer survivors.
According to our estimates approximately one third of
cancer survivors are younger than 65 and survivors in
this age group have more than doubled in the 20 past
years. In this age group resuming as normal a life as
possible includes psychological and/or social support as
well as professional reinsertion.
Cancer is increasingly an illness which might be cured
or which might have the characteristics of a long term
or chronic condition even in patients with advanced
disease. It seems therefore essential to inform patients
and future providers of the long-term effects of cancer
and its treatment and to identify psychosocial needs and
resources to guide prevention and health maintenance
in order to increase the quality of life.
A major limitation of this study is the fact that we
based our estimation on the data from only 4 regional
cancer registers covering about 26% of the population.
As in the USA, where complete prevalence estimates are
based only on SEER registries [35], it is only in 2012 that
the coverage of cancer registration attained 80% in
Switzerland. However the data used are of high quality
as ascertained by the controls performed at the Inter-
national Agency for Research on Cancer [1], with high
levels of microscopic verification (95%) and very low
level of DCO cases (0.6%). Furthermore the data cover
rural alpine and urban areas in the main language
regions (French speaking and German speaking regions)
and include administrative units (cantons) with and
without breast cancer screening programs. Additionally,
the model parameters were chosen by minimizing
squared differences of modelled with observed national
mortality rates, and thus maximizing representativeness
of the available data. The expected mortality rates of the
final models showed very close fit to the national mor-
tality rates. We are therefore confident that estimates
reflect the true situation in Switzerland as close as
possible.
This study is a first step into understanding the num-
ber and characteristics of people living with a cancer
diagnosis in Switzerland. More research is needed to
know the health status, the quality of life and the expect-
ation of cancer survivors, their need in care and support.
This will enable resource planners to better translate the
available information into necessary formation of profes-
sionals, health care and social structures to adequately
meet the specific needs of cancer survivors.
Conclusions
The success of cancer research, early diagnosis and treat-
ment over the last 20 years as well as increases in life
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uals living many years with a cancer diagnosis. Further
research is needed to better understand the special
needs of survivors and to implement care according to
these needs.
Additional file
Additional file 1: Projected cancer prevalence in Switzerland for
2020. This table presents the projected cancer prevalence in terms of
number of cases by gender for major cancer sites in Switzerland for the
year 2020.
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